iRadimed Corporation $IRMD Shares Sold by Conestoga Capital Advisors LLC

Conestoga Capital Advisors LLC reduced its position in shares of iRadimed Corporation (NASDAQ:IRMD) by 22.5% in the 4th quarter, Holdings Channel.com reports. The firm owned 21,215 shares of the medical equipment provider’s stock after selling 6,160 shares during the quarter. Conestoga Capital Advisors LLC’s holdings in iRadimed were worth $2,064,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of IRMD. SG Americas Securities LLC raised its position in shares of iRadimed by 88.6% during the 4th quarter. SG Americas Securities LLC now owns 70,391 shares of the medical equipment provider’s stock valued at $6,848,000 after buying an additional 33,072 shares during the period. Principal Financial Group Inc. purchased a new stake in shares of iRadimed during the 3rd quarter valued at approximately $422,000. Tudor Investment Corp ET AL purchased a new stake in shares of iRadimed during the 3rd quarter valued at approximately $666,000. Raymond James Financial Inc. raised its position in shares of iRadimed by 4.7% during the 2nd quarter. Raymond James Financial Inc. now owns 42,952 shares of the medical equipment provider’s stock valued at $2,568,000 after buying an additional 1,918 shares during the period. Finally, Sei Investments Co. raised its position in shares of iRadimed by 27.5% during the 2nd quarter. Sei Investments Co. now owns 22,472 shares of the medical equipment provider’s stock valued at $1,345,000 after buying an additional 4,848 shares during the period. 92.34% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at iRadimed

In other news, CEO Roger E. Susi sold 3,750 shares of the company’s stock in a transaction on Monday, April 27th. The stock was sold at an average price of $89.16, for a total transaction of $334,350.00. Following the sale, the chief executive officer owned 2,198,750 shares of the company’s stock, valued at approximately $196,040,550. This represents a 0.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 48,750 shares of company stock worth $4,708,950 over the last 90 days. 36.80% of the stock is currently owned by corporate insiders.

iRadimed Stock Performance

iRadimed stock opened at $83.44 on Friday. iRadimed Corporation has a fifty-two week low of $50.31 and a fifty-two week high of $107.90. The firm has a 50 day moving average price of $96.69 and a 200 day moving average price of $93.87. The company has a market capitalization of $1.07 billion, a PE ratio of 47.68 and a beta of 1.11.

iRadimed (NASDAQ:IRMD) last posted its earnings results on Tuesday, February 10th. The medical equipment provider reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.49 by $0.05. iRadimed had a net margin of 26.82% and a return on equity of 23.83%. The firm had revenue of $22.69 million during the quarter, compared to the consensus estimate of $21.60 million. iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. As a group, equities research analysts forecast that iRadimed Corporation will post 1.94 earnings per share for the current year.

iRadimed Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, March 6th. Stockholders of record on Monday, February 23rd were given a dividend of $0.20 per share. This is an increase from iRadimed’s previous quarterly dividend of $0.17. This represents a $0.80 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend was Monday, February 23rd. iRadimed’s dividend payout ratio is currently 45.71%.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on IRMD shares. Lake Street Capital reiterated a “buy” rating and issued a $120.00 target price on shares of iRadimed in a report on Wednesday, February 11th. Roth Mkm reiterated a “buy” rating and issued a $120.00 target price on shares of iRadimed in a report on Tuesday, February 10th. Finally, Freedom Capital upgraded shares of iRadimed to a “strong-buy” rating in a report on Thursday, April 2nd. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $120.00.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.